TechNavio's analysts forecast the Global
Psoriasis Therapeutics market to grow at a CAGR of 4.06 percent over the period
2012-2016. One of the key factors contributing to this market growth is the
increasing uptake of biologics. The Global Psoriasis Therapeutics market has
also been witnessing an increased focus on using combination therapies for
treating psoriasis. However, the adverse side effects associated with psoriatic
drugs could pose a challenge to the growth of this market.
To
Read the Complete Report with TOC Visit:
http://www.marketresearchreports.biz/analysis-details/global-psoriasis-therapeutics-market-2012-2016
TechNavio's report, the Global
Psoriasis Therapeutics Market 2012-2016, has been prepared based on an in-depth
market analysis with inputs from industry experts. The report covers the market
in the Americas, and the EMEA and APAC regions; it also covers the Global
Psoriasis Therapeutics market landscape and its growth prospects in the coming
years. The report also includes a discussion of the key vendors operating in
this market.
The key vendors dominating this
space include Amgen Inc., Pfizer Inc., Janssen Biotech Inc., and Abbvie Inc.
The other vendors mentioned in the
report are AstraZeneca plc, Bristol Myers Squibb Co., Celgene Corp., Celgene
Corp., Eisai Co. Ltd., Eli Lilly and Co., GlaxoSmithKline plc, Incyte Corp.,
Isotechnika Inc., LEO Pharma A/S, Merck & Co. Inc., and Novartis
International AG
UCB S.A. Key questions answered in
this report:
- What will the market size be in 2016 and what will be the growth rate?
- What are key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by key vendors?
- What are the strengths and weaknesses of each of these key vendors?
To
Buy The Copy of This Report Visit:
http://www.marketresearchreports.biz/analysis/172952
Contact
M/s Sheela
90 Sate Street, Suite
700
Albany, NY 12207
USA – Canada Toll
Free: 866-997-4948
No comments:
Post a Comment